2019
DOI: 10.1002/cpt.1484
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Diabetes is a disease defined on the basis of hyperglycemia. There are monogenic forms of diabetes where defining the genetic cause has a dramatic impact on treatment—with patients being able to transition from insulin to sulfonylureas. However, the majority of diabetes is type 2 diabetes. This review outlines the robust evidence accrued to date for pharmacogenetics of metformin, sulfonylureas, thiazolidinediones, and dipeptidyl peptidase‐4 inhibitors but highlights that these variants will only be of clinical… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
22
0
1

Year Published

2019
2019
2024
2024

Publication Types

Select...
6
2

Relationship

1
7

Authors

Journals

citations
Cited by 29 publications
(23 citation statements)
references
References 50 publications
(79 reference statements)
0
22
0
1
Order By: Relevance
“…As a result, this article concentrates on the use of routinely available clinical features to select optimal treatment, although the principles discussed equally apply to the use of genomic or nonroutine biomarkers (6). Recent reviews of the pharmacogenomics of type 2 diabetes drug response are available elsewhere (8,9).…”
mentioning
confidence: 99%
“…As a result, this article concentrates on the use of routinely available clinical features to select optimal treatment, although the principles discussed equally apply to the use of genomic or nonroutine biomarkers (6). Recent reviews of the pharmacogenomics of type 2 diabetes drug response are available elsewhere (8,9).…”
mentioning
confidence: 99%
“…Genotyping can now be undertaken for £30/$40 allowing for the future development of a clinical decision support tool to guide prescribing. 19 If patients were found to have an elevated weighted GRS based on our 23 variant score, shown in Table S1, we propose that an alternative anti-anginal is prescribed. Importantly, this weighted GRS was not associated with early stopping of ISMN.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, a recent systematic review suggested that the role of SLC22A1 variants in individual responses to metformin is population-specific due to high heterogeneity among studied populations [ 102 ]. However, the combined effect of the SLC22A1 genotype is valuable to predict metformin intolerance [ 87 , 103 ].…”
Section: Impact Of Pharmacogenetic Variants In Octs In Precision Mmentioning
confidence: 99%